Anti-Eastern Equine Encephalitis Virus (Clone: EEEV-129)

Home/Infectious Diseases, Monoclonal Antibodies, Primary Monoclonal Antibodies, Recombinant Antibodies/Anti-Eastern Equine Encephalitis Virus (Clone: EEEV-129)

Pricing & Details

Product No.LT570
Eastern Equine Encephalitis Virus
Formats AvailableView All
Product Type
Recombinant Monoclonal Antibody
Alternate Names
EEEV, Triple E
Human IgG1
Prod No.
Add to cart
LT570-250 µg
250 µg
Min: 1
Step: 1
LT570-1.0 mg
1.0 mg
Min: 1
Step: 1
Bulk quantities available. Contact us for pricing.

Antibody Details

Product Details

Reactivity Species
Eastern Equine Encephalitis
Expression Host
A panel of human monoclonal antibodies (mAb), including EEEV-129, was isolated and sequenced from the B cells of a survivor of natural EEEV infection 2
Product Concentration
≥ 5.0 mg/ml
Endotoxin Level
< 1.0 EU/mg as determined by the LAL method
≥95% monomer by analytical SEC
This recombinant monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Storage and Handling
Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one year. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≥ -70°C. Avoid Repeated Freeze Thaw Cycles.
Country of Origin
Standard Overnight on Blue Ice.
Other Applications Reported In Literature ?
N: Antibody EEEV-129 was shown to efficiently neutralize Sindbis virus (SINV)/EEEV, a chimeric virus containing nonstructural proteins of SINV and structural proteins of EEEV strain FL93-939. EEEV-129 exhibited potent neutralizing capacity against SINV/EEEV and pathogenic EEEV strain FL93-939. NOTE: EEEV-129 neutralization was also tested against escape mutant viruses and displays a >10-fold reduction in neutralization potency to SINV/EEEV (M68T).
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.


Clone EEEV-129 activity is directed against the B domain of the E2 glycoprotein. Furthermore, human monoclonal antibody EEEV-129 binds strongly to both SINV/EEEV particles and EEEV E2 glycoprotein. The Fab form of EEEV-129 also neutralizes SINV-EEEV efficiently but with reduced potency, suggesting bivalent or tetravalent interactions as an IgG may contribute to optimal neutralization of SINV/EEEV. Competition-binding studies utilizing biolayer interferometry shows that EEEV-129 competes with domain B-specific murine anti-EEEV mAbs.
Eastern Equine Encephalitis virus (EEEV), one of the most virulent viruses endemic to North America, is a rare mosquito-borne encephalitic alphavirus in the Togaviridae family. Infection leads to a 30% to 75% mortality rate, and up to 90% of survivors develop ongoing neurologic problems1, 2. On average, seven human cases are confirmed yearly in the United States. EEEV is of particular concern because of its potential aerosol spread and lack of available treatments. EEEV prevalence in mosquitoes that feed on humans has recently increased.

Antigen Details

Research Area
Eastern Equine Encephalitis
Infectious Disease

References & Citations

1. Centers for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), Division of Vector-Borne Diseases (DVBD), Link Text
2. Williamson LE, Gilliland T Jr, Yadav PK, et al. Cell. 183(7):1884-1900.e23. 2020.
Elisa Sandwich Protocol

Formats Available

Products are for research use only. Not for use in diagnostic or therapeutic procedures.
Leinco Technologies uses cookies to improve your experience and our website service. By continuing to browse our website, you accept our cookie policy. Ok